Eli Lilly Q1 2026 Earnings April 30: Morningstar Lifts Fair Value to $870 (from $770), Projects 27% Top-Line Growth
Morningstar issued a pre-earnings note ahead of Eli Lilly's April 30 Q1 2026 report raising fair value to $870 from $770 following 2025 results and management guidance. Analysts project 27% top-line growth in 2026 and 20% in 2027, with double-digit growth through end of decade. Mounjaro/Zepbound represented 56% of total sales in 2025, projected to exceed 60% in 2026 with patent protection through 2036. The Q1 print will be the first read on Foundayo launch trajectory after the disappointing 1,390 / 3,707 prescription weeks 1-2.